Use of reboxetine to treat narcolepsy
AssigneeAxsome Therapeutics, Inc.
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
Claims13
A method of reducing the number of cataplexy attacks in a patient having narcolepsy with cataplexy, comprising administering a dosage form to the patient, wherein the dosage form comprises (2RS, αRS)-2-[α-(2-ethoxyphenoxy) benzyl]morpholine methanesulfonate;
- wherein a daily dose that is about 6 mg to about 7 mg of the (2RS, αRS)-2-[α-(2-ethoxyphenoxy) benzyl]morpholine methanesulfonate reboxetine is administered for 7 days, and the dosage form is administered once a day;
- then after 7 days, a daily maintenance dose that is about 13 mg to about 14 mg of the (2RS, αRS)-2-[α-(2-ethoxyphenoxy) benzyl]morpholine methanesulfonate is administered for at least one week, and the dosage form is administered twice a day;
- wherein the patient has a minimum of 7 cataplexy attacks per week prior to receiving the (2RS, αRS)-2-[α-(2-ethoxyphenoxy) benzyl]morpholine methanesulfonate.
Dependencies are inferred from the claim text.